BioCentury
ARTICLE | Company News

Intrepida: Tackling the innate immune system to treat cancer

Intrepida Bio is developing first-in-class mAbs against BAG3 to modulate the TME

October 22, 2019 12:03 PM UTC
Updated on Nov 5, 2019 at 11:06 PM UTC

With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3, which can modulate the innate immune response to inhibit tumor growth in pancreatic cancer.

The company hopes the target will be a differentiator in the already crowded immuno-oncology space...